- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03725384
Daily vs. Every Other Day Oral Iron Supplementation in Patients With Absolute Iron Deficiency Anemia (DEODO)
Daily vs. Every Other Day Oral Iron Supplementation in Patients With Absolute Iron Deficiency Anemia (DEODO): a Multi-centered, Pilot Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a pilot, pragmatic, non-inferiority, open label randomized controlled trial (RCT) in outpatients with iron deficiency anemia to evaluate the effectiveness of oral ferrous sulfate 300mg (60mg elemental iron) once daily versus every other day to improve hemoglobin at 12 weeks post-initiation. The rationale for this study includes: (1) IDA is a common and prevalent condition with potential adverse consequences if left untreated; (2) optimizing effectiveness of oral iron supplementation while minimizing side effects will improve treatment for patients.
Because IDA is a global health problem, common in clinical practice and treatable, this study will have a significant practical impact on how clinicians treat outpatients with iron deficiency anemia and how patients tolerate therapy.
For the patient, the expected benefit from taking part in this study is the potential to improve and treat iron deficiency anemia. These potential changes may lead to improved symptoms associated with iron deficiency anemia, such as cognitive and physical functioning, and fatigue.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook Health Sciences Centre
-
Toronto, Ontario, Canada, M5B 1W8
- St. Michael's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 16 years;
- Outpatients with iron deficiency anemia defined as Hb less than 120 g/L in women or 130g/L in men; AND ferritin less than 30 mcg/L
Exclusion Criteria:
• Pregnancy
- Currently breastfeeding
- Known history of inflammatory bowel disease
- Known history of celiac disease
- Known history of thalassemia or thalassemia trait
- Known inherited bleeding disorder
- Known intolerance or lack of response to oral ferrous gluconate, sulfate or fumarate in the last 12 weeks
- Multivitamin and mineral supplements (35 mg or more of elemental iron per day) in the 2 weeks prior to randomization
- Allergy to oral iron
- Allergy to any of the following medicinal and non-medicinal ingredients in ferrous sulfate: ferrous sulphate, calcium citrate, crospovidone, FD&C Red #40-Aluminum lake, FD&C Yellow #6-Aluminum Lake, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, purified water, talc titanium dioxide
- Allergy to any of the following medicinal and non-medicinal ingredients in vitamin C: Ascorbic acid, Colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose and stearic acid
- Intravenous iron therapy in the past 12 weeks
- On anticoagulant therapy (e.g. warfarin, apixaban, dabigatran, edoxaban, rivaroxaban) initiated in the past 6 months
- Surgery planned in upcoming 12 weeks
- Chemotherapy planned in upcoming 12 weeks
- Blood donation planned in upcoming 12 weeks
- Previously enrolled in the study
- Creatinine clearance less than 30 mL/min
- Hemoglobin less than 80 g/L with active bleeding (defined as WHO grade 2 bleeding or higher in the past week)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Ferrous Sulfate and Vitamin C every other day
Ferrous sulfate 300mg tablet and vitamin C 500mg tablet taken by mouth every other day for 12 weeks
|
oral dose of Ferrous Sulfate (300 mg) every day versus every other day along with vitamin C
Other Names:
Vitamin C 500 Mg tablet every day versus every other day along with ferrous sulfate
Other Names:
|
ACTIVE_COMPARATOR: Ferrous Sulfate and Vitamin C daily
Ferrous sulfate 300mg tablet and vitamin C 500mg tablet taken by mouth every day for 12 weeks
|
oral dose of Ferrous Sulfate (300 mg) every day versus every other day along with vitamin C
Other Names:
Vitamin C 500 Mg tablet every day versus every other day along with ferrous sulfate
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Enrollment
Time Frame: 2 years
|
Enrollment in the trial will be defined as documentation of informed consent for patients approached
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of eligible participants consenting to participate
Time Frame: 2 years
|
Proportion of eligible patients consenting to participate
|
2 years
|
Proportion of consenting patients receiving the allocated treatment
Time Frame: 2 years
|
Proportion of consenting patients receiving the allocated treatment
|
2 years
|
Treated patients completing 4 and 12 week laboratory tests
Time Frame: 2 years
|
Proportion of treated patients completing 4 week and 12 week laboratory tests
|
2 years
|
Proportion of treated patients completing side effect questionnaire at week 4, 8 and 12
Time Frame: 2 years
|
Proportion of treated patients completing 4 week, 8 week and 12 week side effect questionnaire
|
2 years
|
Proportion of treated patients completing 4 week, 8 week and 12 week FACIT-fatigue scale
Time Frame: 2 years
|
Proportion of treated patients completing 4 week, 8 week and 12 week FACIT-fatigue scale
|
2 years
|
Proportion of treatment doses taken per protocol based on pill count
Time Frame: 12 weeks
|
Proportion of treatment doses taken as per protocol based on pill count
|
12 weeks
|
Proportion of treated patients taking 90% of prescribed doses
Time Frame: 2 years
|
Proportion of treated patients taking at least 90% of their prescribed doses
|
2 years
|
Proportion of treated patients requiring a step down in therapy
Time Frame: 2 years
|
Proportion of treated patients requiring a step down in therapy
|
2 years
|
Hemoglobin increment
Time Frame: 12 weeks
|
Hemoglobin increment at 4 and 12 weeks is defined as the 4 or 12 week hemoglobin value minus the baseline hemoglobin value
|
12 weeks
|
Proportion with complete hemoglobin response
Time Frame: 2 years
|
Proportion with complete hemoglobin response defined as hemoglobin greater than or equal to 120 g/L in women; and 130 g/L in men at 4 weeks and 12 weeks
|
2 years
|
Reticulocyte count
Time Frame: 12 weeks
|
Change in reticulocyte count at 4 and 12 weeks defined as the 4 or 12 week reticulocyte count minus the baseline reticulocyte count
|
12 weeks
|
Change in ferritin, at 12 weeks defined as the value at 12 weeks minus the baseline value
Time Frame: 12 weeks
|
Change in ferritin, at 12 weeks defined as the value at 12 weeks minus the baseline value
|
12 weeks
|
Change in serum iron at 12 weeks defined as the value at 12 weeks minus the baseline value
Time Frame: 12 weeks
|
Change in serum iron at 12 weeks defined as the value at 12 weeks minus the baseline value
|
12 weeks
|
Change in TSAT at 12 weeks defined as the value at 12 weeks minus the baseline value
Time Frame: 12 weeks
|
Change in TSAT at 12 weeks defined as the value at 12 weeks minus the baseline value
|
12 weeks
|
FACIT-fatigue scale at 4, 8 and 12 weeks
Time Frame: 12 weeks
|
Quality of life (FACIT-fatigue scale) at 4, 8 and 12 weeks
|
12 weeks
|
Proportion with side effects and type of side effects at 4, 8 and 12 weeks as determined by the oral iron side effect questionnaire
Time Frame: 12 weeks
|
Proportion with side effects and type of side effects at 4, 8 and 12 weeks as determined by the oral iron side effect questionnaire
|
12 weeks
|
Proportion of patients who stop taking oral iron due to side effects at 4 and 12 weeks
Time Frame: 12 weeks
|
Proportion of patients who stop taking oral iron due to side effects at 4 and 12 weeks
|
12 weeks
|
Number of patients in need of escalation therapy
Time Frame: 2 years
|
Need for escalation in therapy (increase in oral iron regimen from every other day to daily, need for intravenous iron, need for transfusion, visit to emergency department related to anemia) assessed at 12 weeks
|
2 years
|
Proportion of patients with a drop in hemoglobin of 10 g/L or more at weeks 4 and 12
Time Frame: 2 years
|
Proportion of patients with a drop in hemoglobin of 10 g/L or more at weeks 4 and 12
|
2 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Dr.Yulia Lin, Sunnybrook Health Sciences Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Hematologic Diseases
- Nutrition Disorders
- Anemia, Hypochromic
- Iron Metabolism Disorders
- Malnutrition
- Anemia, Iron-Deficiency
- Anemia
- Deficiency Diseases
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Protective Agents
- Trace Elements
- Micronutrients
- Vitamins
- Antioxidants
- Ascorbic Acid
- Iron
Other Study ID Numbers
- CTO ID 1534
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anemia
-
SanofiActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)United States, Austria, China, Denmark, Germany, Hungary, Italy, Spain, United Kingdom
-
SanofiTerminatedWarm Autoimmune Hemolytic Anemia (wAIHA)United Kingdom, Belgium, Netherlands, France, United States, Germany, Hungary, Italy
-
Hospital Universitario Dr. Jose E. GonzalezCompletedPernicious Anemia | Megaloblastic Anemia NosMexico
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingSevere Aplastic Anemia | Idiopathic Aplastic Anemia | Moderate Aplastic Anemia Requiring Transfusions
-
Abdelwahed, Mai Mahmoud Mohamed, M.D.UnknownAnemia During PregnancyEgypt
-
University of California, DavisInstituto Mexicano del Seguro Social; Thrasher Research Fund; Mexican National... and other collaboratorsCompleted
-
Incyte CorporationActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)Spain, United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, United Kingdom
-
Peking Union Medical College HospitalRecruiting
-
Alexion PharmaceuticalsWithdrawnWarm Autoimmune Hemolytic AnemiaUnited States
Clinical Trials on Ferrous Sulfate 300Mg Tablet
-
Columbia UniversityNational Institute of General Medical Sciences (NIGMS)RecruitingAnemia | Postoperative Cognitive Dysfunction | Adolescent Idiopathic Scoliosis | Spinal Fusion | Perioperative/Postoperative Complications | Neuromuscular Scoliosis | Iron DeficienciesUnited States
-
Weill Medical College of Cornell UniversityCompletedAnemic, Critically Ill PatientsUnited States
-
Universidade Federal FluminenseActive, not recruitingDysbiosis | Anemia of Chronic Kidney Disease | Chronic Renal Disease | Iron-Deficiency AnemiaBrazil
-
Swiss Federal Institute of TechnologyUniversity of Oxford; St. Luke's Medical CenterTerminatedIron-deficiencyPhilippines
-
National Cardiovascular Center Harapan Kita Hospital...CompletedHeart Failure, Systolic | Iron-deficiency Anemia
-
Iowa State UniversityCompletedIron-deficiency | Iron Deficiency Anemia | Iron Deficiency Anemia Treatment | Iron Deficiency Anaemia Due to Dietary CausesUnited States
-
Duzce UniversityCompletedIron Deficiency Anemia | Subclinical HypothyroidismTurkey
-
Instituto de Desarrollo e Investigaciones Pediátricas...UnknownIron-deficiency | AnemiaArgentina
-
Indiana UniversityCompletedAutosomal Dominant Hypophosphatemic RicketsUnited States
-
Swiss Federal Institute of TechnologyUniversity Hospital, Zürich; ETH ZurichCompletedAnemia | Iron Deficiency Anemia | Iron DeficiencySwitzerland